These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35624536)

  • 1. Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure.
    Zong X; Fan Q; Yang Q; Pan R; Zhuang L; Tao R
    ESC Heart Fail; 2022 Aug; 9(4):2645-2653. PubMed ID: 35624536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure.
    Romano KA; Nemet I; Prasad Saha P; Haghikia A; Li XS; Mohan ML; Lovano B; Castel L; Witkowski M; Buffa JA; Sun Y; Li L; Menge CM; Demuth I; König M; Steinhagen-Thiessen E; DiDonato JA; Deb A; Bäckhed F; Tang WHW; Naga Prasad SV; Landmesser U; Van Wagoner DR; Hazen SL
    Circ Heart Fail; 2023 Jan; 16(1):e009972. PubMed ID: 36524472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenylacetylglutamine increases the susceptibility of ventricular arrhythmias in heart failure mice by exacerbated activation of the TLR4/AKT/mTOR signaling pathway.
    Fu H; Kong B; Zhu J; Huang H; Shuai W
    Int Immunopharmacol; 2023 Mar; 116():109795. PubMed ID: 36736224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of two intestinal bacterial metabolites (trimethylamine N-oxide and phenylacetylglutamine) in human serum samples of patients with T2DM and AMI using a liquid chromatography tandem mass spectrometry method.
    Tang Y; Zou Y; Cui J; Ma X; Zhang L; Yu S; Qiu L
    Clin Chim Acta; 2022 Nov; 536():162-168. PubMed ID: 36191613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis.
    Fu Y; Yang Y; Fang C; Liu X; Dong Y; Xu L; Chen M; Zuo K; Wang L
    Front Cardiovasc Med; 2022; 9():944155. PubMed ID: 36110409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure.
    Zhang Z; Cai B; Sun Y; Deng H; Wang H; Qiao Z
    Front Cardiovasc Med; 2022; 9():1076806. PubMed ID: 36704458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut-Derived Metabolite Phenylacetylglutamine and White Matter Hyperintensities in Patients With Acute Ischemic Stroke.
    Yu F; Feng X; Li X; Luo Y; Wei M; Zhao T; Xia J
    Front Aging Neurosci; 2021; 13():675158. PubMed ID: 34393756
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic Significance of Interleukin-34 (IL-34) in Patients With Chronic Heart Failure With or Without Renal Insufficiency.
    Tao R; Fan Q; Zhang H; Xie H; Lu L; Gu G; Wang F; Xi R; Hu J; Chen Q; Niu W; Shen W; Zhang R; Yan X
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28365566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenylacetylglutamine, a Novel Biomarker in Acute Ischemic Stroke.
    Yu F; Li X; Feng X; Wei M; Luo Y; Zhao T; Xiao B; Xia J
    Front Cardiovasc Med; 2021; 8():798765. PubMed ID: 35004911
    [No Abstract]   [Full Text] [Related]  

  • 10. Dysbiosis of Gut Microbiota and Metabolite Phenylacetylglutamine in Coronary Artery Disease Patients With Stent Stenosis.
    Fang C; Zuo K; Fu Y; Li J; Wang H; Xu L; Yang X
    Front Cardiovasc Med; 2022; 9():832092. PubMed ID: 35402559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Association of serum albumin level and clinical outcomes among heart failure patients receiving cardiac resynchronization therapy].
    Yang SW; Liu ZM; Mi JR; Liu SY; Ding LG; Chen KP; Hua W; Zhang S
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):204-208. PubMed ID: 28316176
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic value of heart failure in hemodialysis-dependent end-stage renal disease patients with myocardial fibrosis quantification by extracellular volume on cardiac magnetic resonance imaging.
    Xu HY; Yang ZG; Zhang Y; Peng WL; Xia CC; Li ZL; He Y; Xu R; Rao L; Peng Y; Li YM; Gao HL; Guo YK
    BMC Cardiovasc Disord; 2020 Jan; 20(1):12. PubMed ID: 31924159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders.
    Andrade F; Vitoria I; Martín Hernández E; Pintos-Morell G; Correcher P; Puig-Piña R; Quijada-Fraile P; Peña-Quintana L; Marquez AM; Villate O; García Silva MT; de Las Heras J; Ceberio L; Rodrigues E; Almeida Campos T; Yahyaoui R; Blasco J; Vives-Piñera I; Gil D; Del Toro M; Ruiz-Pons M; Cañedo E; Barba Romero MA; García-Jiménez MC; Aldámiz-Echevarría L
    J Pharm Biomed Anal; 2019 Nov; 176():112798. PubMed ID: 31394303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum potassium levels provide prognostic information in symptomatic heart failure beyond traditional clinical variables.
    Toledo CC; Vellosa Schwartzmann P; Miguel Silva L; da Silva Ferreira G; Bianchini Cardoso F; Citelli Ribeiro V; Paim LR; Antunes-Correa LM; Carvalho Sposito A; Matos Souza JR; Modolo R; Nadruz W; Fernandes de Carvalho LS; Coelho-Filho OR
    ESC Heart Fail; 2021 Jun; 8(3):2133-2143. PubMed ID: 33734611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased p-cresyl sulfate level is independently associated with poor outcomes in patients with heart failure.
    Wang CH; Cheng ML; Liu MH; Shiao MS; Hsu KH; Huang YY; Lin CC; Lin JF
    Heart Vessels; 2016 Jul; 31(7):1100-8. PubMed ID: 26135926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of new-onset refractory congestive heart failure using gated myocardial perfusion SPECT imaging in patients with known or suspected coronary artery disease subanalysis of the J-ACCESS database.
    Nakata T; Hashimoto A; Wakabayashi T; Kusuoka H; Nishimura T
    JACC Cardiovasc Imaging; 2009 Dec; 2(12):1393-400. PubMed ID: 20083074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure.
    Trøseid M; Ueland T; Hov JR; Svardal A; Gregersen I; Dahl CP; Aakhus S; Gude E; Bjørndal B; Halvorsen B; Karlsen TH; Aukrust P; Gullestad L; Berge RK; Yndestad A
    J Intern Med; 2015 Jun; 277(6):717-26. PubMed ID: 25382824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The limited prognostic role of echocardiograms in short-term follow-up after acute decompensated heart failure: An analysis of the Korean Heart Failure (KorHF) Registry.
    Kim SH; Kim HJ; Han S; Yoo BS; Choi DJ; Kim JJ; Jeon ES; Cho MC; Chae SC; Ryu KH
    PLoS One; 2017; 12(12):e0188938. PubMed ID: 29261675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology.
    Zafrir B; Salman N; Crespo-Leiro MG; Anker SD; Coats AJ; Ferrari R; Filippatos G; Maggioni AP; Mebazaa A; Piepoli MF; Ruschitzka F; Paniagua-Martin MJ; Segovia J; Laroche C; Amir O;
    Eur J Heart Fail; 2016 Jul; 18(7):859-68. PubMed ID: 27198159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD.
    Poesen R; Claes K; Evenepoel P; de Loor H; Augustijns P; Kuypers D; Meijers B
    J Am Soc Nephrol; 2016 Nov; 27(11):3479-3487. PubMed ID: 27230658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.